Amgen and Harvard Pilgrim agree to first cardiovascular outcomes based refund contract for Repatha (evolocumab)

Amgen

2 May 2017 - Harvard Pilgrim refines the utilisation management criteria to help high risk cardiovascular disease patients access Repatha.

Amgen today announced from the World Medical Innovation Forum focused on cardiovascular disease that Harvard Pilgrim, a health services company providing healthcare coverage for nearly 2.7 million customers in the northeast region of the U.S., has signed an outcomes based refund contract with Amgen for Repatha (evolocumab). 

This first-of-its-kind contract is based on the Repatha cardiovascular outcomes data that were recently presented at the American College of Cardiology 66th Annual Scientific Session. 

The contract provides Harvard Pilgrim with a rebate for the cost of Repatha for an eligible patient who has a heart attack or stroke while on Repatha.

Read Amgen press release

Michael Wonder

Posted by:

Michael Wonder